Indian vaccine maker calls on US to relax export restrictions

New Delhi (AP)-CEO of Serum Institute of India, the world’s largest vaccine maker and a key supplier of UN-backed COVAX facilities, will make a jab to President Joe Biden on Twitter.

Indian vaccine makers and experts are concerned that exports of critical raw materials have been suspended as a result of the United States’ use of the Defense Production Act to increase its vaccine production. This has hampered vaccine production in other parts of the world.

Moderna CEO Stéphane Bancel said in an online event Tuesday that an export ban has prevented American vaccine makers from exporting shots globally, creating a shortage.

“On behalf of the vaccine industry outside the United States, if we truly unite to defeat the virus, we humbly lift the embargo on raw material exports from the United States so that we can increase vaccine production. Please, “writes Adar Poonawalla. , CEO of Indian Serum Institute.

He previously told The Associated Press that moving away from US suppliers could delay the production of the Novavax-developed COVID-19 vaccine by up to six months. The Serum Institute and Novavax have signed a contract to supply 1.1 billion doses of vaccine to COVAX and distribute them fairly worldwide.

India’s Serum Institute of India has suspended exports to COVAX after increased domestic demand due to a catastrophic surge in infections in India.

Over 200,000 new infections have been detected in the last 24 hours, imposing virus restrictions in major cities such as Mumbai and New Delhi. Hospitals are overwhelmed and authorities are struggling to vaccinate enough people to delay the epidemic. But in doing so, India relies heavily on AstraZeneca shots made by the Indian Serum Institute.

Poonawalla said the lack of raw materials, such as the specific media needed for microbial growth, would prevent the Serum Institute from expanding production of the vaccine developed by Novavax.

The company planned to make up to 40 million shots of vaccine each month.

Enhancing the production of this shot could also help India. Novavax has filed an emergency use of the vaccine with regulators in Europe, the United States, and the World Health Organization. Once approved, India will be able to use shots under new regulations that make it easier to approve vaccines approved by the United Kingdom, the United States, Europe, Japan, or WHO.


The Associated Press’s Department of Health Sciences is supported by the Department of Science Education at the Howard Hughes Medical Institute. AP is solely responsible for all content.

Sign up for our daily newsletter

Copyright © 2021 The Washington Times, LLC.

Indian vaccine maker calls on US to relax export restrictions

Source link Indian vaccine maker calls on US to relax export restrictions

Back to top button